TMPRSS2 and COVID-19: Camostat and Nafamostat were demonstrated to be effective TMPRSS2 inhibitors [8,9,12] and are in clinical trials for COVID-19 treatment (ClinicalTrials.gov (accessed on 28 March 2021) Identifier: NCT04321096 for Camostat and NCT04352400 for Nafamostat).